von Willebrand factor antigen (vWF-Ag): A non-invasive predictor of treatment response and serious adverse events in HCV patients with interferon triple therapy-Reference-Cited by-同舟云学术

von Willebrand factor antigen (vWF-Ag): A non-invasive predictor of treatment response and serious adverse events in HCV patients with interferon triple therapy

Published:2016-10 Issue:10 Volume:48 Page:1194-1199
ISSN:1590-8658
Container-title:Digestive and Liver Disease
language:en
Short-container-title:Digestive and Liver Disease

Author:

Rutter Karoline,Etschmaier Alexandra,Ferlitsch Monika,Maieron Andreas,Hametner Stephanie,Horvatits Thomas,Paternostro Rafael,Salzl Petra,Reiberger Thomas,Peck-Radosavljevic Markus,Quehenberger Peter,Hofer Harald,Trauner Michael,Ferenci Peter,Ferlitsch Arnulf

Publisher

Elsevier BV

Subject

Gastroenterology,Hepatology

Reference35 articles.

1. Telaprevir for previously untreated chronic hepatitis C virus infection;Jacobson;New England Journal of Medicine,2011

2. Boceprevir for untreated chronic HCV genotype 1 infection;Poordad;New England Journal of Medicine,2011

3. Triple therapy in treatment-experienced patients with hcv-cirrhosis in a multicentre cohort of the French early access programme (anrs co20-cupic) – nct01514890;Hezode;Journal of Hepatology,2013

4. Safety profile of boceprevir and telaprevir in chronic hepatitis C: real world experience from HCV-TARGET;Gordon;Journal of Hepatology,2015

5. First-generation protease inhibitor-triple therapy: SVR 24, safety, and predictors of response in a large single center cohort;Werner;Virology Journal,2015

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Platelet activation is upregulated in cirrhotic patients with portal vein thrombosis;Thrombosis and Haemostasis;2023-10-12

2. Mechanism, diagnosis, and treatment of portal vein thrombosis in cirrhosis;World Chinese Journal of Digestology;2021-06-28